NCT00410553View on ClinicalTrials.gov

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 14, 2006

Primary Completion Date

October 24, 2012

Study Completion Date

October 24, 2012

Conditions
Adult Solid NeoplasmRecurrent Ovarian CarcinomaRecurrent Uterine Corpus CarcinomaStage III Ovarian Cancer AJCC v6 and v7Stage III Uterine Corpus Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Uterine Corpus Cancer AJCC v7
Interventions
DRUG

Eribulin Mesylate

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (2)

K1Y 4E9

Ottawa Hospital-Civic Campus, Ottawa

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00410553 - Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | Biotech Hunter | Biotech Hunter